Skip to main content

Table 3 Meta-analysis results for the prevalence of CFS/ME

From: Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)

GroupN. of dataaRandom effects model (%)Heterogeneity (P < 0.01, P = 0%)
 Prevalence95% CIQT2I2 (%)
Total560.68[0.48; 0.97]8602.901.719999.4
Sex
 Male240.86[0.58; 1.27]279.890.666691.8
 Female241.36[0.91; 2.02]822.640.800397.2
 Total481.04[0.76; 1.41]1481.760.947196.8
Study participants
 Community330.76[0.53; 1.10]3286.471.036399.0
 Primary care230.63[0.37; 1.10]2732.101.774599.2
Population group
 General population (≥ 18 years)
  Male230.89[0.60; 1.32]276.230.660792.0
  Female231.36[0.91; 2.04]818.300.800997.3
  Total440.65[0.43; 0.99]7717.651.851899.4
  Children/adolescents (< 18 years)70.55[0.22; 1.35]538.131.431998.9
  Specific population51.31[0.61; 2.78]80.540.665795.0
Case definition
 CDC-1994 [22]340.89[0.60; 1.33]3871.641.369199.1
 Holmes [23]80.17[0.06; 0.49]101.721.889093.1
  Australian [25]40.79[0.05; 12.55]1002.437.886099.7
  Oxford [24]41.41[0.68; 2.93]35.170.446891.5
  CCC [27] ECD [26] PVES [28] NICE [29]b40.17[0.04; 0.83]1200.672.586499.8
Diagnostic method
 Interview (medical test −)221.14[0.76; 1.72]1675.910.826998.7
 Interview(medical test +)230.95[0.69; 1.31]365.720.520894.0
 Physician diagnosis60.09[0.05; 0.13]200.490.295297.5
 Medical records50.52[0.16; 1.71]1197.281.836099.7
  1. Refer to supplementary Additional file: Figs. 1, 2, 3, 4, 5, 6, 7
  2. aTotal number of prevalence data points
  3. bCCC, Canadian Consensus Criteria; ECD, epidemiological case definition; PVES, post viral exhaustion syndrome; and NICE, National Institute for Health and Care Excellence guideline 2007; two studies with no verification of case definition and defined criteria were excluded